LianBio Announces Presentation Of Data From Phase 2a Study Of Infigratinib In Patients With Gastric Cancer At ESMO Congress 2023
Portfolio Pulse from Benzinga Newsdesk
LianBio (NASDAQ:LIAN) has presented efficacy and safety data from a Phase 2a study of infigratinib in Chinese patients with advanced gastric cancer at the ESMO Congress 2023. The study showed a confirmed objective response rate of 23.8% and a disease control rate of 76.2%. The drug was well tolerated with no treatment-related adverse events leading to dose discontinuation, death, or drug-induced liver injury. Infigratinib has received Breakthrough Therapy Designation from the China National Medical Products Administration for the treatment of gastric cancer.
October 25, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LianBio's Phase 2a study data of infigratinib shows promising results in treating advanced gastric cancer. The drug has received Breakthrough Therapy Designation in China, indicating its potential for future commercial success.
The positive results from the Phase 2a study of infigratinib and its Breakthrough Therapy Designation in China are significant indicators of the drug's potential. This could lead to increased investor confidence in LianBio, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100